Wolters Kluwer has expanded its artificial intelligence-driven offerings across both healthcare and legal sectors, with new deployments that highlight the company’s continued push into data-enabled professional workflows.
The Dutch information services group has rolled out its Medi-Span medication decision support solution at The Christie NHS Foundation Trust, the largest cancer centre in Europe. The system is designed to assist clinicians with prescribing decisions and improve patient safety by providing real-time drug information and clinical guidance.
In parallel, the company has strengthened its position in the legal technology space through the integration of its Libra AI workspace with Kleos, a cloud-based practice management platform used by legal professionals across several European markets. The integration is intended to streamline legal workflows, improve document handling, and enhance productivity through AI-assisted tools.
These developments underscore Wolters Kluwer’s broader strategy of embedding AI capabilities into its core professional information services, spanning both healthcare and legal domains. The company continues to position itself as a provider of specialized software and data solutions rather than a traditional publisher.
On the market side, Wolters Kluwer has shown mixed share price performance in recent months. The stock recently traded at €66.08, reflecting an 8.4% gain over the past week, but a 7.4% decline over the past month. Longer-term performance remains weaker, with the share price down 24.9% year-to-date and 58.5% over the past year, extending losses across multi-year periods.
Despite the pressure, valuation models referenced by analysts suggest the stock may be trading below estimated fair value, with some forecasts implying significant upside relative to current levels. However, the company’s recent momentum remains fragile, and investors are closely watching how quickly new AI-driven products translate into sustained revenue growth.
At the same time, the group’s financial structure remains a point of attention, with elevated debt levels potentially influencing its capacity to scale further investments in artificial intelligence and platform integration. Market observers continue to track adoption of its AI tools, particularly in clinical and legal environments, as a key indicator of long-term performance.